Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Authors:
Michael D Huband
Michael D Huband
The University of Texas MD Anderson Cancer Center
United States
Michael A Pfaller
Michael A Pfaller
JMI Laboratories
North Liberty | United States
Dee Shortridge
Dee Shortridge
Northwestern University
United States
Robert K Flamm
Robert K Flamm
Discovery and Clinical Microbiology
United States

J Glob Antimicrob Resist 2019 Feb 27. Epub 2019 Feb 27.

JMI Laboratories, North Liberty, IA, United States.

Objectives: Omadacycline is an aminomethylcycline antibacterial (oral and intravenous once-daily formulation) that recently (October 2018) received FDA approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) against selected organism groups. In this study, omadacycline and comparators were tested against 14000 non-duplicate bacterial isolates collected prospectively during 2017 from medical centres in Europe (EUR; 7000 isolates) and the United States (USA; 7000 isolates).

Methods: Omadacycline was tested by broth microdilution following CLSI M07-A11 (2018) methods.

Results: A total of 98.7% ofStaphylococcus aureus isolates were susceptible (S) to omadacycline (MIC, 0.12/0.25 mg/L; ABSSSI breakpoints) including 96.5% of MRSA, 99.8% of MSSA, and 93.9% of tetracycline-resistant strains. Omadacycline activity was similar for Streptococcus pneumoniae (MIC 0.06/0.12 mg/L; 98.6%S [CABP breakpoints]), Streptococcus anginosus group (MIC 0.06/0.06 mg/L; 100.0%S [ABSSSI breakpoints]), and Streptococcus pyogenes (MIC 0.06/0.12 mg/L; 97.7%S [ABSSSI breakpoints]). Omadacycline demonstrated activity against Enterobacter cloacae species complex isolates (MIC, 2/4 mg/L; 91.2%S [ABSSSI breakpoints]), Klebsiella pneumoniae (MIC, 2/8 mg/L; 87.5%S [CABP and ABSSSI breakpoints]), and inhibited 99.1% of Escherichia coli (MIC, 0.5/2 mg/L) isolates at ≤4 mg/L. Omadacycline was active against Haemophilus influenzae (MIC, 0.5/1 mg/L; 99.8%S [CABP breakpoints]) including all β-lactamase positive isolates and inhibited 100.0% of Moraxella catarrhalis isolates at ≤0.25 mg/L.

Conclusions: The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgar.2019.02.017DOI Listing
February 2019
5 Reads

Publication Analysis

Top Keywords

[absssi breakpoints]
12
omadacycline
9
united states
8
isolates united
8
breakpoints] streptococcus
8
gram-positive gram-negative
8
mic
8
mic 006/012 mg/l
8
[cabp breakpoints]
8
isolates
8
pneumoniae mic
8
omadacycline activity
8
breakpoints]
6
mic 012/025 mg/l
4
012/025 mg/l absssi
4
haemophilus influenzae
4
998%s [cabp
4
susceptible omadacycline
4
omadacycline mic
4
05/1 mg/l 998%s
4

Similar Publications